Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts.
Additional Information
The Egyptian pharmaceutical market is the largest in the region, worth an estimated US$2.2 billion in 2008. Pharmaceutical sector activity centres around two major areas: the introduction of WTO TRIPS-compliant legislation on intellectual property rights, and the state of the drug pricing system. These issues have caused much friction between the government, local producers and multinationals; local producers face challenges complying with IP laws.
Egypt is a leading exporter to Arab, Asian and African regions, although exports have declined in recent years. Rising costs for imported raw materials, due to currency depreciation, have acted as a brake on local production. Annual market growth is around 5.0% in US dollar terms.
Privatisation is a growing trend within the Egyptian healthcare industry, thus the sector is undergoing considerable change. Prior to the 1990s, the sector was predominantly State-controlled, with the private sector playing only a minimal role in the provision of healthcare.
The private sector now plays an increasingly important role in healthcare provision, emerging largely as a result of the declining standard of public sector care. Out-of-pocket payments for drugs have also increased in recent years.